Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
Add more filters










Publication year range
1.
Nat Immunol ; 25(5): 834-846, 2024 May.
Article in English | MEDLINE | ID: mdl-38561495

ABSTRACT

Cancer remains one of the leading causes of mortality worldwide, leading to increased interest in utilizing immunotherapy strategies for better cancer treatments. In the past decade, CD103+ T cells have been associated with better clinical prognosis in patients with cancer. However, the specific immune mechanisms contributing toward CD103-mediated protective immunity remain unclear. Here, we show an unexpected and transient CD61 expression, which is paired with CD103 at the synaptic microclusters of T cells. CD61 colocalization with the T cell antigen receptor further modulates downstream T cell antigen receptor signaling, improving antitumor cytotoxicity and promoting physiological control of tumor growth. Clinically, the presence of CD61+ tumor-infiltrating T lymphocytes is associated with improved clinical outcomes, mediated through enhanced effector functions and phenotype with limited evidence of cellular exhaustion. In conclusion, this study identified an unconventional and transient CD61 expression and pairing with CD103 on human immune cells, which potentiates a new target for immune-based cellular therapies.


Subject(s)
Antigens, CD , Apyrase , Integrin alpha Chains , Receptors, Antigen, T-Cell , Signal Transduction , Animals , Humans , Mice , Antigens, CD/metabolism , Antigens, CD/immunology , Cell Line, Tumor , Cytotoxicity, Immunologic , Integrin alpha Chains/metabolism , Lymphocytes, Tumor-Infiltrating/immunology , Lymphocytes, Tumor-Infiltrating/metabolism , Neoplasms/immunology , Neoplasms/therapy , Receptors, Antigen, T-Cell/metabolism , Receptors, Antigen, T-Cell/immunology , Signal Transduction/immunology , T-Lymphocytes, Cytotoxic/immunology
2.
Proc Natl Acad Sci U S A ; 120(6): e2211368120, 2023 02 07.
Article in English | MEDLINE | ID: mdl-36730202

ABSTRACT

Ligation of T cell receptor (TCR) to peptide-MHC (pMHC) complexes initiates signaling leading to T cell activation and TCR ubiquitination. Ubiquitinated TCR is then either internalized by the T cell or released toward the antigen-presenting cell (APC) in extracellular vesicles. How these distinct fates are orchestrated is unknown. Here, we show that clathrin is first recruited to TCR microclusters by HRS and STAM2 to initiate release of TCR in extracellular vesicles through clathrin- and ESCRT-mediated ectocytosis directly from the plasma membrane. Subsequently, EPN1 recruits clathrin to remaining TCR microclusters to enable trans-endocytosis of pMHC-TCR conjugates from the APC. With these results, we demonstrate how clathrin governs bidirectional membrane exchange at the immunological synapse through two topologically opposite processes coordinated by the sequential recruitment of ecto- and endocytic adaptors. This provides a scaffold for direct two-way communication between T cells and APCs.


Subject(s)
Clathrin , Immunological Synapses , Clathrin/metabolism , Receptors, Antigen, T-Cell , T-Lymphocytes , Lymphocyte Activation
3.
J Extracell Biol ; 2(3): e74, 2023 Mar.
Article in English | MEDLINE | ID: mdl-38938417

ABSTRACT

CD8+ T lymphocytes play vital roles in killing infected or deranged host cells, recruiting innate immune cells, and regulating other aspects of immune responses. Like any other cell, CD8+ T cells also produce extracellular particles. These include extracellular vesicles (EVs) and non-vesicular extracellular particles (NVEPs). T cell-derived EVs are proposed to mediate cell-to-cell signalling, especially in the context of inflammatory responses, autoimmunity, and infectious diseases. CD8+ T cells also produce supramolecular attack particles (SMAPs), which are in the same size range as EVs and mediate a component of T cell mediated killing. The isolation technique selected will have a profound effect on yield, purity, biochemical properties and function of T cell-derived particles; making it important to directly compare different approaches. In this study, we compared commonly used techniques (membrane spin filtration, ultracentrifugation, or size exclusion liquid chromatography) to isolate particles from activated human CD8+ T cells and validated our results by single-particle methods, including nanoparticle tracking analysis, flow cytometry, electron microscopy and super-resolution microscopy of the purified sample as well as bulk proteomics and lipidomics analyses to evaluate the quality and nature of enriched T cell-derived particles. Our results show that there is a trade-off between the yield and the quality of T cell-derived particles. Furthermore, the protein and lipid composition of the particles is dramatically impacted by the isolation technique applied. We conclude that from the techniques evaluated, size exclusion liquid chromatography offers the highest quality of T cell derived EVs and SMAPs with acceptable yields for compositional and functional studies.

4.
Nat Commun ; 13(1): 3460, 2022 06 16.
Article in English | MEDLINE | ID: mdl-35710644

ABSTRACT

The immunological synapse is a molecular hub that facilitates the delivery of three activation signals, namely antigen, costimulation/corepression and cytokines, from antigen-presenting cells (APC) to T cells. T cells release a fourth class of signaling entities, trans-synaptic vesicles (tSV), to mediate bidirectional communication. Here we present bead-supported lipid bilayers (BSLB) as versatile synthetic APCs to capture, characterize and advance the understanding of tSV biogenesis. Specifically, the integration of juxtacrine signals, such as CD40 and antigen, results in the adaptive tailoring and release of tSV, which differ in size, yields and immune receptor cargo compared with steadily released extracellular vesicles (EVs). Focusing on CD40L+ tSV as model effectors, we show that PD-L1 trans-presentation together with TSG101, ADAM10 and CD81 are key in determining CD40L vesicular release. Lastly, we find greater RNA-binding protein and microRNA content in tSV compared with EVs, supporting the specialized role of tSV as intercellular messengers.


Subject(s)
CD40 Ligand , Extracellular Vesicles , CD40 Ligand/metabolism , Extracellular Vesicles/metabolism , Immunological Synapses , Synaptic Vesicles , T-Lymphocytes
5.
J Vis Exp ; (182)2022 04 01.
Article in English | MEDLINE | ID: mdl-35435908

ABSTRACT

Antigen-presenting cells (APCs) present three activating signals to T cells engaged in physical contact: 1) antigen, 2) costimulation/corepression, and 3) soluble cytokines. T cells release two kinds of effector particles in response to activation: trans-synaptic vesicles (tSVs) and supramolecular attack particles, which transfer intercellular messengers and mediate cytotoxicity, respectively. These entities are quickly internalized by APCs engaged in physical contact with T cells, making their characterization daunting. This paper presents the protocol to fabricate and use Bead-Supported Lipid Bilayers (BSLBs) as antigen-presenting cell (APC) mimetics to capture and analyze these trans-synaptic particles. Also described are the protocols for the absolute measurements of protein densities on cell surfaces, the reconstitution of BSLBs with such physiological levels, and the flow cytometry procedure for tracking synaptic particle release by T cells. This protocol can be adapted to study the effects of individual proteins, complex ligand mixtures, pathogen virulence determinants, and drugs on the effector output of T cells, including helper T cells, cytotoxic T lymphocytes, regulatory T cells, and chimeric antigen receptor-expressing T cells (CART).


Subject(s)
Antigen-Presenting Cells , Lipid Bilayers , Lipid Bilayers/metabolism , Lymphocyte Activation , Synapses , T-Lymphocytes, Cytotoxic , T-Lymphocytes, Helper-Inducer
6.
FEBS J ; 288(4): 1070-1090, 2021 02.
Article in English | MEDLINE | ID: mdl-32681663

ABSTRACT

Understanding the broad variety of functions encoded in cellular membranes requires experimental systems mimicking both their biochemical composition and biophysical properties. Here, we review the interplay between membrane components and the physical properties of the plasma membrane worth considering for biomimetic studies. Later, we discuss the main advantages and caveats of different model membrane systems. We further expand on how the use of model systems has contributed to the understanding of immune cell signaling, with a specific focus on the immunological synapse. We discuss the similarities of immune synapses observed for innate and adaptive immune cells and focus on the physical principles underlying these similarities.


Subject(s)
Cell Membrane/metabolism , Immunological Synapses/metabolism , Lipid Bilayers/metabolism , Membrane Proteins/metabolism , Signal Transduction , Animals , B-Lymphocytes/metabolism , Humans , Phagocytes/metabolism , T-Lymphocytes/metabolism
7.
Front Cell Dev Biol ; 8: 608484, 2020.
Article in English | MEDLINE | ID: mdl-33537301

ABSTRACT

A central process in immunity is the activation of T cells through interaction of T cell receptors (TCRs) with agonistic peptide-major histocompatibility complexes (pMHC) on the surface of antigen presenting cells (APCs). TCR-pMHC binding triggers the formation of an extensive contact between the two cells termed the immunological synapse, which acts as a platform for integration of multiple signals determining cellular outcomes, including those from multiple co-stimulatory/inhibitory receptors. Contributors to this include a number of chemokine receptors, notably CXC-chemokine receptor 4 (CXCR4), and other members of the G protein-coupled receptor (GPCR) family. Although best characterized as mediators of ligand-dependent chemotaxis, some chemokine receptors are also recruited to the synapse and contribute to signaling in the absence of ligation. How these and other GPCRs integrate within the dynamic structure of the synapse is unknown, as is how their normally migratory Gαi-coupled signaling is terminated upon recruitment. Here, we report the spatiotemporal organization of several GPCRs, focusing on CXCR4, and the G protein Gαi2 within the synapse of primary human CD4+ T cells on supported lipid bilayers, using standard- and super-resolution fluorescence microscopy. We find that CXCR4 undergoes orchestrated phases of reorganization, culminating in recruitment to the TCR-enriched center. This appears to be dependent on CXCR4 ubiquitination, and does not involve stable interactions with TCR microclusters, as viewed at the nanoscale. Disruption of this process by mutation impairs CXCR4 contributions to cellular activation. Gαi2 undergoes active exclusion from the synapse, partitioning from centrally-accumulated CXCR4. Using a CRISPR-Cas9 knockout screen, we identify several diverse GPCRs with contributions to T cell activation, most significantly the sphingosine-1-phosphate receptor S1PR1, and the oxysterol receptor GPR183. These, and other GPCRs, undergo organization similar to CXCR4; including initial exclusion, centripetal transport, and lack of receptor-TCR interactions. These constitute the first observations of GPCR dynamics within the synapse, and give insights into how these receptors may contribute to T cell activation. The observation of broad GPCR contributions to T cell activation also opens the possibility that modulating GPCR expression in response to cell status or environment may directly regulate responsiveness to pMHC.

8.
Front Immunol ; 9: 2875, 2018.
Article in English | MEDLINE | ID: mdl-30581437

ABSTRACT

The Human Respiratory Syncytial Virus (hRSV) and the Human Metapneumovirus (hMPV) are two pneumoviruses that are leading agents causing acute lower respiratory tract infections (ALRTIs) affecting young infants, the elderly, and immunocompromised patients worldwide. Since these pathogens were first discovered, many approaches for the licensing of safe and effective vaccines have been explored being unsuccessful to date. We have previously described that immunization with recombinant strains of Mycobacterium bovis Bacillus Calmette-Guérin (rBCG) expressing the hRSV nucleoprotein (rBCG-N) or the hMPV phosphoprotein (rBCG-P) induced immune protection against each respective virus. These vaccines efficiently promoted viral clearance without significant lung damage, mainly through the induction of a T helper 1 cellular immunity. Here we show that upon viral challenge, rBCG-immunized mice developed a protective humoral immunity, characterized by production of antibodies specific for most hRSV and hMPV proteins. Further, isotype switching from IgG1 to IgG2a was observed in mice immunized with rBCG vaccines and correlated with an increased viral clearance, as compared to unimmunized animals. Finally, sera obtained from animals immunized with rBCG vaccines and infected with their respective viruses exhibited virus neutralizing capacity and protected naïve mice from viral replication and pulmonary disease. These results support the notion that the use of rBCG strains could be considered as an effective vaccination approach against other respiratory viruses with similar biology as hRSV and hMPV.


Subject(s)
BCG Vaccine/immunology , Immunity, Humoral , Mycobacterium bovis/immunology , Respiratory Tract Infections/prevention & control , Animals , BCG Vaccine/administration & dosage , Cell Line, Tumor , Disease Models, Animal , Humans , Metapneumovirus/genetics , Metapneumovirus/immunology , Mice , Mice, Inbred BALB C , Nucleoproteins/administration & dosage , Nucleoproteins/genetics , Nucleoproteins/immunology , Recombinant Proteins/administration & dosage , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Respiratory Syncytial Virus, Human/genetics , Respiratory Syncytial Virus, Human/immunology , Respiratory Tract Infections/immunology , Respiratory Tract Infections/virology , Th1 Cells/immunology , Th1 Cells/metabolism , Vaccination/methods , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunology , Viral Proteins/administration & dosage , Viral Proteins/genetics , Viral Proteins/immunology , Virus Replication/immunology
9.
Viral Immunol ; 31(4): 306-314, 2018 05.
Article in English | MEDLINE | ID: mdl-29373084

ABSTRACT

The human metapneumovirus (hMPV) is the second leading cause globally of acute infection of the respiratory tract in children, infecting the upper and lower airways. The hMPV may induce an inappropriate Th2-type immune response, which causes severe pulmonary inflammation, leading to the obstruction of airways. Despite its severe epidemiological relevance, no vaccines are currently available for the prevention of hMPV-induced illness. In this investigation, we demonstrated that immunization of mice with the recombinant hMPV nucleoprotein (hMPV-N) mixed with the AbISCO-100 adjuvant reduced viral replication in lungs following challenge with the virus. We found that immunized mice had reduced weight loss, decreased granulocytes in the lung, an increased level of specific nucleoprotein antibodies of IgG1 and IgG2a-isotypes, and a local profile of Th1/Th17-type cytokines. Our results suggest that immunization with the hMPV-N and the AbISCO-100 adjuvant induces a reduction of viral infection and could be considered for the development of an hMPV vaccine.


Subject(s)
Immunization , Metapneumovirus/immunology , Nucleoproteins/administration & dosage , Paramyxoviridae Infections/immunology , Viral Vaccines/immunology , Adjuvants, Immunologic/pharmacology , Animals , Antibodies, Viral/blood , Antibodies, Viral/classification , Cytokines/analysis , Dendritic Cells/classification , Disease Models, Animal , Gene Expression/drug effects , Granulocytes , Humans , Lung/drug effects , Lung/pathology , Lung/virology , Mice , Mice, Inbred BALB C , Nucleoproteins/genetics , Nucleoproteins/isolation & purification , Paramyxoviridae Infections/prevention & control , Pneumonia/virology , RNA, Viral/analysis , Viral Vaccines/pharmacology , Weight Loss
10.
J Immunol ; 199(1): 212-223, 2017 07 01.
Article in English | MEDLINE | ID: mdl-28566367

ABSTRACT

Human respiratory syncytial virus (hRSV) is the leading cause of severe lower respiratory tract infections in children. The development of novel prophylactic and therapeutic antiviral drugs against hRSV is imperative to control the burden of disease in the susceptible population. In this study, we examined the effects of inducing the activity of the host enzyme heme oxygenase-1 (HO-1) on hRSV replication and pathogenesis on lung inflammation induced by this virus. Our results show that after hRSV infection, HO-1 induction with metalloporphyrin cobalt protoporphyrin IX significantly reduces the loss of body weight due to hRSV-induced disease. Further, HO-1 induction also decreased viral replication and lung inflammation, as evidenced by a reduced neutrophil infiltration into the airways, with diminished cytokine and chemokine production and reduced T cell function. Concomitantly, upon cobalt protoporphyrin IX treatment, there is a significant upregulation in the production of IFN-α/ß mRNAs in the lungs. Furthermore, similar antiviral and protective effects occur by inducing the expression of human HO-1 in MHC class II+ cells in transgenic mice. Finally, in vitro data suggest that HO-1 induction can modulate the susceptibility of cells, especially the airway epithelial cells, to hRSV infection.


Subject(s)
Heme Oxygenase-1/metabolism , Lung/immunology , Respiratory Syncytial Virus Infections/physiopathology , Respiratory Syncytial Virus Infections/virology , Respiratory Syncytial Virus, Human/physiology , Animals , Cell Line , Cytokines/biosynthesis , Cytokines/immunology , DNA Replication , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Heme Oxygenase-1/genetics , Humans , Interferon-alpha/biosynthesis , Interferon-alpha/immunology , Interferon-beta/immunology , Lung/metabolism , Lung/pathology , Lung/virology , Mice , Protoporphyrins/administration & dosage , Protoporphyrins/pharmacology , Respiratory Syncytial Virus Infections/immunology , T-Lymphocytes/immunology , Virus Attachment , Virus Internalization , Virus Replication
11.
Vaccine ; 35(5): 757-766, 2017 02 01.
Article in English | MEDLINE | ID: mdl-28065474

ABSTRACT

Human respiratory syncytial virus (hRSV) is a major health burden worldwide, causing the majority of hospitalizations in children under two years old due to bronchiolitis and pneumonia. HRSV causes year-to-year outbreaks of disease, which also affects the elderly and immunocompromised adults. Furthermore, both hRSV morbidity and epidemics are explained by a consistently high rate of re-infections that take place throughout the patient life. Although significant efforts have been invested worldwide, currently there are no licensed vaccines to prevent hRSV infection. Here, we describe that a recombinant Bacillus Calmette-Guerin (BCG) vaccine expressing the nucleoprotein (N) of hRSV formulated under current good manufacture practices (cGMP rBCG-N-hRSV) confers protective immunity to the virus in mice. Our results show that a single dose of the GMP rBCG-N-hRSV vaccine retains its capacity to protect mice against a challenge with a disease-causing infection of 1×107 plaque-forming units (PFUs) of the hRSV A2 clinical strain 13018-8. Compared to unimmunized infected controls, vaccinated mice displayed reduced weight loss and less infiltration of neutrophils within the airways, as well as reduced viral loads in bronchoalveolar lavages, parameters that are characteristic of hRSV infection in mice. Also, ex vivo re-stimulation of splenic T cells at 28days post-immunization activated a repertoire of T cells secreting IFN-γ and IL-17, which further suggest that the rBCG-N-hRSV vaccine induced a mixed, CD8+ and CD4+ T cell response capable of both restraining viral spread and preventing damage of the lungs. All these features support the notion that rBCG-N-hRSV is a promising candidate vaccine to be used in humans to prevent the disease caused by hRSV in the susceptible population.


Subject(s)
BCG Vaccine/administration & dosage , CD8-Positive T-Lymphocytes/drug effects , Immunity, Cellular/drug effects , Respiratory Syncytial Virus Infections/prevention & control , Respiratory Syncytial Virus Vaccines/administration & dosage , Respiratory Syncytial Virus, Human/drug effects , Th17 Cells/drug effects , Animals , BCG Vaccine/genetics , BCG Vaccine/immunology , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/virology , Humans , Immunization Schedule , Immunogenicity, Vaccine , Interferon-gamma/biosynthesis , Interferon-gamma/immunology , Interleukin-17/biosynthesis , Interleukin-17/immunology , Lung/drug effects , Lung/immunology , Lung/virology , Lymphocyte Activation/drug effects , Mice , Mice, Inbred BALB C , Nucleoproteins/genetics , Nucleoproteins/immunology , Respiratory Syncytial Virus Infections/immunology , Respiratory Syncytial Virus Infections/virology , Respiratory Syncytial Virus Vaccines/genetics , Respiratory Syncytial Virus Vaccines/immunology , Respiratory Syncytial Virus, Human/immunology , Respiratory Syncytial Virus, Human/pathogenicity , Th1 Cells/drug effects , Th1 Cells/immunology , Th1 Cells/virology , Th17 Cells/immunology , Th17 Cells/virology , Vaccines, Synthetic , Viral Proteins/genetics , Viral Proteins/immunology
12.
J Cell Biochem ; 118(2): 351-360, 2017 02.
Article in English | MEDLINE | ID: mdl-27356893

ABSTRACT

Osteosarcomas are the most prevalent bone tumors in pediatric patients, but can also occur later in life. Bone tumors have the potential to metastasize to lung and occasionally other vital organs. To understand how osteosarcoma cells interact with their micro-environment to support bone tumor progression and metastasis, we analyzed secreted proteins and exosomes from three human osteosarcoma cell lines. Exosome isolation was validated by transmission electron microscopy (TEM) and immuno-blotting for characteristic biomarkers (CD63, CD9, and CD81). Exosomal and soluble proteins (less than 100 kDa) were identified by mass spectrometry analysis using nanoLC-MS/MS and classified by functional gene ontology clustering. We identified a secretome set of >3,000 proteins for both fractions, and detected proteins that are either common or unique among the three osteosarcoma cell lines. Protein ontology comparison of proteomes from exosomes and exosome-free fractions revealed differences in the enrichment of functional categories associated with different biological processes, including those related to tumor progression (i.e., angiogenesis, cell adhesion, and cell migration). The secretome characteristics of osteosarcoma cells are consistent with the pathological properties of tumor cells with metastatic potential. J. Cell. Biochem. 118: 351-360, 2017. © 2016 Wiley Periodicals, Inc.


Subject(s)
Antigens, CD/metabolism , Biomarkers, Tumor/metabolism , Bone Neoplasms/metabolism , Exosomes/metabolism , Neoplasm Proteins/metabolism , Osteosarcoma/metabolism , Cell Line, Tumor , Humans
13.
Clin Microbiol Rev ; 29(4): 795-818, 2016 10.
Article in English | MEDLINE | ID: mdl-27413096

ABSTRACT

Globally, as a leading agent of acute respiratory tract infections in children <5 years of age and the elderly, the human metapneumovirus (HMPV) has gained considerable attention. As inferred from studies comparing vaccinated and experimentally infected mice, the acquired immune response elicited by this pathogen fails to efficiently clear the virus from the airways, which leads to an exaggerated inflammatory response and lung damage. Furthermore, after disease resolution, there is a poor development of T and B cell immunological memory, which is believed to promote reinfections and viral spread in the community. In this article, we discuss the molecular mechanisms that shape the interactions of HMPV with host tissues that lead to pulmonary pathology and to the development of adaptive immunity that fails to protect against natural infections by this virus.


Subject(s)
Adaptive Immunity , Metapneumovirus/immunology , Metapneumovirus/physiology , Paramyxoviridae Infections/immunology , Paramyxoviridae Infections/pathology , Respiratory Tract Infections/pathology , Animals , Disease Models, Animal , Host-Pathogen Interactions , Humans , Mice , Respiratory Tract Infections/immunology , Respiratory Tract Infections/virology
14.
Immunology ; 147(1): 55-72, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26451966

ABSTRACT

Human respiratory syncytial virus (hRSV) is the leading cause of infant hospitalization related to respiratory disease. Infection with hRSV produces abundant infiltration of immune cells into the airways, which combined with an exacerbated pro-inflammatory immune response can lead to significant damage to the lungs. Human RSV re-infection is extremely frequent, suggesting that this virus may have evolved molecular mechanisms that interfere with host adaptive immunity. Infection with hRSV can be reduced by administering a humanized neutralizing antibody against the virus fusion protein in high-risk infants. Although neutralizing antibodies against hRSV effectively block the infection of airway epithelial cells, here we show that both, bone marrow-derived dendritic cells (DCs) and lung DCs undergo infection with IgG-coated virus (hRSV-IC), albeit abortive. Yet, this is enough to negatively modulate DC function. We observed that such a process is mediated by Fcγ receptors (FcγRs) expressed on the surface of DCs. Remarkably, we also observed that in the absence of hRSV-specific antibodies FcγRIII knockout mice displayed significantly less cellular infiltration in the lungs after hRSV infection, compared with wild-type mice, suggesting a potentially harmful, IgG-independent role for this receptor in hRSV disease. Our findings support the notion that FcγRs can contribute significantly to the modulation of DC function by hRSV and hRSV-IC. Further, we provide evidence for an involvement of FcγRIII in the development of hRSV pathogenesis.


Subject(s)
Dendritic Cells/metabolism , Lung/metabolism , Lymphocyte Activation , Receptors, IgG/metabolism , Respiratory Syncytial Virus Infections/metabolism , Respiratory Syncytial Virus, Human/pathogenicity , T-Lymphocytes/metabolism , Adaptive Immunity , Animals , Antibodies, Neutralizing/pharmacology , Antibodies, Viral/immunology , Antibodies, Viral/metabolism , Antiviral Agents/pharmacology , Cells, Cultured , Coculture Techniques , Cytokines/metabolism , Dendritic Cells/drug effects , Dendritic Cells/immunology , Dendritic Cells/virology , Disease Models, Animal , Immunoglobulin G/immunology , Immunoglobulin G/metabolism , Lung/drug effects , Lung/immunology , Lung/virology , Lymphocyte Activation/drug effects , Mice, Inbred C57BL , Mice, Knockout , Palivizumab/pharmacology , Receptors, IgG/deficiency , Receptors, IgG/genetics , Receptors, IgG/immunology , Respiratory Syncytial Virus Infections/drug therapy , Respiratory Syncytial Virus Infections/genetics , Respiratory Syncytial Virus Infections/immunology , Respiratory Syncytial Virus Infections/virology , Respiratory Syncytial Virus, Human/drug effects , Respiratory Syncytial Virus, Human/immunology , Signal Transduction , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , T-Lymphocytes/virology , Viral Load , Virus Replication
15.
Crit Rev Immunol ; 35(3): 185-202, 2015.
Article in English | MEDLINE | ID: mdl-26559227

ABSTRACT

Acute respiratory tract infections (ARTIs) are the major cause of child mortality worldwide. The human metapneumovirus (hMPV) is one of the leading causes of child hospitalizations due to pneumonia. The adaptive immune response generated by the host against hMPV is usually inefficient at protecting from reinfections, which is repeat throughout life, from childhood to old age. Despite considerable research efforts, to date there are no licensed vaccines to prevent respiratory disease caused by hMPV infection. In this article we review current vaccine strategies tested in animal models and the implication of such studies in understanding the different immune cell populations that contribute to hMPV clearance and the prevention and resolution of lung inflammation upon exposure to the virus.


Subject(s)
Lung/immunology , Metapneumovirus/physiology , Paramyxoviridae Infections/immunology , Respiratory Tract Infections/immunology , Viral Vaccines/immunology , Acute Disease , Aged , Animals , Child , Disease Models, Animal , Humans , Lung/pathology , Lung/virology , Viral Load
16.
Expert Opin Investig Drugs ; 24(12): 1613-30, 2015.
Article in English | MEDLINE | ID: mdl-26457559

ABSTRACT

INTRODUCTION: Human respiratory syncytial virus (hRSV) is the leading cause of acute lower respiratory tract infections worldwide in infants, as well as an important pathogen affecting the elderly and immunocompromised individuals. Despite more than a half a century of research, no licensed vaccines are available and only palivizumab has been approved to use in humans, mostly recommended or limited to high risk infants. Therefore, novel therapeutic and preventive drugs need to be developed to fight this major human pathogen. AREAS COVERED: This review discusses current therapeutic approaches in preclinical and clinical stages, aimed at controlling or preventing hRSV infection. These methods include passive immunization, experimental drugs, vaccine candidates and maternal immunization. EXPERT OPINION: Based on the results of various immunization strategies and therapeutic approaches, it is likely that the most effective strategy against hRSV will be a prophylactic tool aimed at developing a strong antiviral T-cell response capable of both, promoting the generation of hRSV-specific high affinity antibodies and leading the protective immunity required to prevent the disease caused by this virus. Alternatively, if prophylactic strategies fail, antiviral drugs and novel passive immunity strategies could significantly contribute to reducing hospitalization rates in susceptible individuals.


Subject(s)
Antiviral Agents/administration & dosage , Respiratory Syncytial Virus Infections/drug therapy , Respiratory Syncytial Virus Vaccines/administration & dosage , Aged , Animals , Antiviral Agents/therapeutic use , Drug Design , Humans , Immunocompromised Host , Infant , Palivizumab/administration & dosage , Palivizumab/therapeutic use , Respiratory Syncytial Virus Infections/epidemiology , Respiratory Syncytial Virus Infections/prevention & control , Respiratory Syncytial Virus, Human/isolation & purification , Respiratory Tract Infections/drug therapy , Respiratory Tract Infections/prevention & control , Respiratory Tract Infections/virology
17.
Eur J Immunol ; 45(6): 1680-95, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25763996

ABSTRACT

Human metapneumovirus (hMPV) is a leading cause of acute respiratory tract infections in children and the elderly. The mechanism by which this virus triggers an inflammatory response still remains unknown. Here, we evaluated whether the thymic stromal lymphopoietin (TSLP) pathway contributes to lung inflammation upon hMPV infection. We found that hMPV infection promotes TSLP expression both in human airway epithelial cells and in the mouse lung. hMPV infection induced lung infiltration of OX40L(+) CD11b(+) DCs. Mice lacking the TSLP receptor deficient mice (tslpr(-/-) ) showed reduced lung inflammation and hMPV replication. These mice displayed a decreased number of neutrophils as well a reduction in levels of thymus and activation-regulated chemokine/CCL17, IL-5, IL-13, and TNF-α in the airways upon hMPV infection. Furthermore, a higher frequency of CD4(+) and CD8(+) T cells was found in tslpr(-/-) mice compared to WT mice, which could contribute to controlling viral spread. Depletion of neutrophils in WT and tslpr(-/-) mice decreased inflammation and hMPV replication. Remarkably, blockage of TSLP or OX40L with specific Abs reduced lung inflammation and viral replication following hMPV challenge in mice. Altogether, these results suggest that activation of the TSLP pathway is pivotal in the development of pulmonary pathology and pulmonary hMPV replication.


Subject(s)
Cytokines/metabolism , Metapneumovirus/physiology , Paramyxoviridae Infections/metabolism , Paramyxoviridae Infections/virology , Pneumonia, Viral/metabolism , Pneumonia, Viral/virology , Signal Transduction , Animals , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/pharmacology , Cell Line , Cytokines/genetics , Dendritic Cells/immunology , Dendritic Cells/metabolism , Disease Models, Animal , Epithelial Cells/metabolism , Epithelial Cells/virology , Gene Expression , Humans , Interleukin-33 , Interleukin-8/genetics , Interleukin-8/metabolism , Interleukins/genetics , Interleukins/metabolism , Macrophages, Alveolar/immunology , Macrophages, Alveolar/metabolism , Metapneumovirus/drug effects , Mice , Neutrophils/immunology , Neutrophils/metabolism , OX40 Ligand/antagonists & inhibitors , OX40 Ligand/genetics , OX40 Ligand/metabolism , Paramyxoviridae Infections/drug therapy , Paramyxoviridae Infections/genetics , Paramyxoviridae Infections/pathology , Pneumonia, Viral/drug therapy , Pneumonia, Viral/genetics , Pneumonia, Viral/pathology , Receptors, Cytokine/antagonists & inhibitors , Receptors, Cytokine/deficiency , Signal Transduction/drug effects , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , T-Lymphocyte Subsets/pathology , Virus Replication , Thymic Stromal Lymphopoietin
18.
Virulence ; 5(7): 740-51, 2014.
Article in English | MEDLINE | ID: mdl-25513775

ABSTRACT

Globally, the human respiratory syncytial virus (hRSV) is the major cause of lower respiratory tract infections (LRTIs) in infants and children younger than 2 years old. Furthermore, the number of hospitalizations due to LRTIs has shown a sustained increase every year due to the lack of effective vaccines against hRSV. Thus, this virus remains as a major public health and economic burden worldwide. The lung pathology developed in hRSV-infected humans is characterized by an exacerbated inflammatory and Th2 immune response. In order to rationally design new vaccines and therapies against this virus, several studies have focused in elucidating the interactions between hRSV virulence factors and the host immune system. Here, we discuss the main features of hRSV biology, the processes involved in virus recognition by the immune system and the most relevant mechanisms used by this pathogen to avoid the antiviral host response.


Subject(s)
Adaptive Immunity , Respiratory Syncytial Virus Infections/immunology , Respiratory Syncytial Virus, Human/immunology , Respiratory Syncytial Virus, Human/pathogenicity , Viral Proteins/physiology , Virulence Factors/physiology , Child , Child, Preschool , Genome, Viral , Humans , Immune Evasion , Immunity, Innate , Infant , Lymphocyte Activation , Respiratory Syncytial Virus, Human/physiology , Viral Proteins/genetics , Viral Proteins/immunology
19.
Proc Natl Acad Sci U S A ; 111(31): E3214-23, 2014 Aug 05.
Article in English | MEDLINE | ID: mdl-25056968

ABSTRACT

Human respiratory syncytial virus (hRSV) is the leading cause of bronchiolitis and pneumonia in young children worldwide. The recurrent hRSV outbreaks and reinfections are the cause of a significant public health burden and associate with an inefficient antiviral immunity, even after disease resolution. Although several mouse- and human cell-based studies have shown that hRSV infection prevents naïve T-cell activation by antigen-presenting cells, the mechanism underlying such inhibition remains unknown. Here, we show that the hRSV nucleoprotein (N) could be at least partially responsible for inhibiting T-cell activation during infection by this virus. Early after infection, the N protein was expressed on the surface of epithelial and dendritic cells, after interacting with trans-Golgi and lysosomal compartments. Further, experiments on supported lipid bilayers loaded with peptide-MHC (pMHC) complexes showed that surface-anchored N protein prevented immunological synapse assembly by naive CD4(+) T cells and, to a lesser extent, by antigen-experienced T-cell blasts. Synapse assembly inhibition was in part due to reduced T-cell receptor (TCR) signaling and pMHC clustering at the T-cell-bilayer interface, suggesting that N protein interferes with pMHC-TCR interactions. Moreover, N protein colocalized with the TCR independently of pMHC, consistent with a possible interaction with TCR complex components. Based on these data, we conclude that hRSV N protein expression at the surface of infected cells inhibits T-cell activation. Our study defines this protein as a major virulence factor that contributes to impairing acquired immunity and enhances susceptibility to reinfection by hRSV.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Cell Membrane/metabolism , Immunological Synapses/immunology , Nucleoproteins/metabolism , Respiratory Syncytial Virus, Human/immunology , Viral Proteins/metabolism , Animals , Brefeldin A/pharmacology , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/pathology , Cell Communication , Cell Line , Cell Membrane/drug effects , Dendritic Cells/drug effects , Dendritic Cells/metabolism , Golgi Apparatus/drug effects , Golgi Apparatus/metabolism , Histocompatibility Antigens/immunology , Humans , Immunological Synapses/drug effects , Lipid Bilayers/metabolism , Lymphocyte Activation/drug effects , Mice , Mice, Inbred C57BL , Peptides/immunology , Protein Transport/drug effects , Receptors, Antigen, T-Cell/immunology , Respiratory Syncytial Virus Infections/immunology , Signal Transduction/drug effects , Signal Transduction/immunology , Virus Replication/drug effects
20.
J Immunol ; 192(1): 214-23, 2014 Jan 01.
Article in English | MEDLINE | ID: mdl-24319265

ABSTRACT

Along with the human respiratory syncytial virus (hRSV), the human metapneumovirus (hMPV) is one of the leading causes of childhood hospitalization and a major health burden worldwide. Unfortunately, owing to an inefficient immunological memory, hMPV infection provides limited immune protection against reinfection. Furthermore, hMPV can induce an inadequate Th2 type immune response that causes severe lung inflammation, leading to airway obstruction. Similar to hRSV, it is likely that an effective clearance of hMPV would require a balanced Th1 type immunity by the host, involving the activation of IFN-γ-secreting T cells. A recognized inducer of Th1 immunity is Mycobacterium bovis bacillus Calmette-Guérin (BCG), which has been used in newborns for many decades and in several countries as a tuberculosis vaccine. We have previously shown that immunization with BCG strains expressing hRSV Ags can induce an efficient immune response that protects against this virus. In this study, we show that immunization with rBCG strains expressing the phosphoprotein from hMPV also can induce protective Th1 immunity. Mice immunized with rBCG were protected against weight loss, airway inflammation, and viral replication in the lungs after hMPV infection. Our rBCG vaccine also induced the activation of hMPV-specific T cells producing IFN-γ and IL-2, which could protect from hMPV infection when transferred to recipient mice. These data strongly support the notion that rBCG induces protective Th1 immunity and could be considered as an efficient vaccine against hMPV.


Subject(s)
BCG Vaccine/immunology , Metapneumovirus/immunology , Paramyxoviridae Infections/immunology , Th1 Cells/immunology , Adoptive Transfer , Animals , Antibodies, Bacterial/immunology , Cell Line , Cytokines/biosynthesis , Disease Models, Animal , Humans , Immunity, Cellular , Immunoglobulin G/immunology , Lung/immunology , Lung/pathology , Lung/virology , Metapneumovirus/metabolism , Mice , Paramyxoviridae Infections/pathology , Paramyxoviridae Infections/prevention & control , Phosphoproteins/immunology , Phosphoproteins/metabolism , T-Lymphocytes/immunology , T-Lymphocytes/pathology , Vaccines, Synthetic , Viral Proteins/immunology , Viral Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...